Do erythropoietic-stimulating agents relieve fatigue? A review of reviews

David T Eton, David Cella

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interest in the efficacy and potential deleterious consequences of treatment with erythropoietic-stimulating agents (ESAs) is very high. Recently, the ESAs have come under intense scrutiny as several clinical trials have shown their use to be associated with an increased risk of thrombosis, and a concern for increased mortality risk in oncology. In this context, attention to the effect of ESAs upon fatigue and other aspects of quality of life has tended to be lost. To aid inclusion of this endpoint in the important consideration of risks and benefits of ESA therapy, we summarize the many reviews that have been conducted on this topic. The ten selected reviews were all conducted systematically or were otherwise comprehensive. While these reviews acknowledge an overall positive fatigue or quality-of-life effect, some were equivocal about the meaningfulness or magnitude of the benefit. The overall evidence from these reviews supports a fatigue and overall quality-of-life benefit from treatment with ESAs that is unlikely to be due to chance. This information should be included in the risk/benefit consideration of these controversial agents.

Original languageEnglish (US)
Pages (from-to)181-194
Number of pages14
JournalCancer Treatment and Research
Volume157
DOIs
StatePublished - 2011

Fingerprint

Fatigue
Quality of Life
Thrombosis
Clinical Trials
Mortality
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Do erythropoietic-stimulating agents relieve fatigue? A review of reviews. / Eton, David T; Cella, David.

In: Cancer Treatment and Research, Vol. 157, 2011, p. 181-194.

Research output: Contribution to journalArticle

@article{ca720c9158e14b0ca5b8a6fcb54dc466,
title = "Do erythropoietic-stimulating agents relieve fatigue? A review of reviews",
abstract = "Interest in the efficacy and potential deleterious consequences of treatment with erythropoietic-stimulating agents (ESAs) is very high. Recently, the ESAs have come under intense scrutiny as several clinical trials have shown their use to be associated with an increased risk of thrombosis, and a concern for increased mortality risk in oncology. In this context, attention to the effect of ESAs upon fatigue and other aspects of quality of life has tended to be lost. To aid inclusion of this endpoint in the important consideration of risks and benefits of ESA therapy, we summarize the many reviews that have been conducted on this topic. The ten selected reviews were all conducted systematically or were otherwise comprehensive. While these reviews acknowledge an overall positive fatigue or quality-of-life effect, some were equivocal about the meaningfulness or magnitude of the benefit. The overall evidence from these reviews supports a fatigue and overall quality-of-life benefit from treatment with ESAs that is unlikely to be due to chance. This information should be included in the risk/benefit consideration of these controversial agents.",
author = "Eton, {David T} and David Cella",
year = "2011",
doi = "10.1007/978-1-4419-7073-2_11",
language = "English (US)",
volume = "157",
pages = "181--194",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Do erythropoietic-stimulating agents relieve fatigue? A review of reviews

AU - Eton, David T

AU - Cella, David

PY - 2011

Y1 - 2011

N2 - Interest in the efficacy and potential deleterious consequences of treatment with erythropoietic-stimulating agents (ESAs) is very high. Recently, the ESAs have come under intense scrutiny as several clinical trials have shown their use to be associated with an increased risk of thrombosis, and a concern for increased mortality risk in oncology. In this context, attention to the effect of ESAs upon fatigue and other aspects of quality of life has tended to be lost. To aid inclusion of this endpoint in the important consideration of risks and benefits of ESA therapy, we summarize the many reviews that have been conducted on this topic. The ten selected reviews were all conducted systematically or were otherwise comprehensive. While these reviews acknowledge an overall positive fatigue or quality-of-life effect, some were equivocal about the meaningfulness or magnitude of the benefit. The overall evidence from these reviews supports a fatigue and overall quality-of-life benefit from treatment with ESAs that is unlikely to be due to chance. This information should be included in the risk/benefit consideration of these controversial agents.

AB - Interest in the efficacy and potential deleterious consequences of treatment with erythropoietic-stimulating agents (ESAs) is very high. Recently, the ESAs have come under intense scrutiny as several clinical trials have shown their use to be associated with an increased risk of thrombosis, and a concern for increased mortality risk in oncology. In this context, attention to the effect of ESAs upon fatigue and other aspects of quality of life has tended to be lost. To aid inclusion of this endpoint in the important consideration of risks and benefits of ESA therapy, we summarize the many reviews that have been conducted on this topic. The ten selected reviews were all conducted systematically or were otherwise comprehensive. While these reviews acknowledge an overall positive fatigue or quality-of-life effect, some were equivocal about the meaningfulness or magnitude of the benefit. The overall evidence from these reviews supports a fatigue and overall quality-of-life benefit from treatment with ESAs that is unlikely to be due to chance. This information should be included in the risk/benefit consideration of these controversial agents.

UR - http://www.scopus.com/inward/record.url?scp=78349280292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349280292&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7073-2_11

DO - 10.1007/978-1-4419-7073-2_11

M3 - Article

C2 - 21052957

AN - SCOPUS:78349280292

VL - 157

SP - 181

EP - 194

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -